The Dragon PLC Trial (DRAGON-PLC)

计划入组 358 人 · 首次发布于 2025 年 4 月 6 日

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

计划入组 38 人 · 首次发布于 2015 年 12 月 18 日

Sedative-Anxiolytic Effects on Simulated Driving Performance

计划入组 15 人 · 首次发布于 2017 年 9 月 29 日

Gene-activated beta-interferon(Shire Plc)

Calaspargase pegol(Asparlas)

CFTR mRNA therapy (Shire/CFFT)

Shire Ltd.

United Kingdom

Shire Development LLC

United States

SHIRE DEVELOPMENT, LLC

United States

FDA Approves Lialda for Maintenance of Remission in Ulcerative Colitis Patients

KALA BIO Names Todd Bazemore as Permanent CEO Ahead of Pivotal Phase 2b Trial Readout

Ultragenyx Appoints Eric Olson as Chief Business Officer to Lead Rare Disease Pipeline Expansion